Pancreatic Cancer Research

ResearcherSanofi (France)Active in the last 2 years

Nicola Fazio

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6869-0704; OpenAlex author ID A5020435379. Sources: ClinicalTrials.gov.

Their work

Papers
6 (first author 0, last author 3)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2013: 1 trial · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 6

  1. Development and validation of an epidemiological risk score for early detection of pancreatic cancer in high-risk individuals within the IMAGene project. Co-author DOI 10.1093/ije/dyag064↗
  2. Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis. Last author DOI 10.1016/j.ctrv.2022.102338↗
  3. Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinoma-Is It Based on Evidence or Clinical Wisdom? Last author DOI 10.1001/jamaoncol.2021.3603↗
  4. Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast? Co-author DOI 10.1200/jco.20.00419↗
  5. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcin… Co-author DOI 10.1200/jco.20.00590↗
  6. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A sys… Last author DOI 10.1016/j.ctrv.2019.101895↗

Trials 1

  1. A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus Principal investigator NCT02305810↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lorenzo Gervaso · 3 shared papers, 2021–2026 · strength 0.60
  2. Florian Lordick · 1 shared paper, 2021 · strength 0.22
  3. Serena Oliveri · 1 shared paper, 2026 · strength 0.21
  4. Mireia Obón‐Santacana · 1 shared paper, 2026 · strength 0.21
  5. Cindy Canivet · 1 shared paper, 2026 · strength 0.21
  6. Lois Riobó‐Mayo · 1 shared paper, 2026 · strength 0.21
  7. Louis Buscail · 1 shared paper, 2026 · strength 0.21
  8. Barbara Bournet · 1 shared paper, 2026 · strength 0.21
  9. Victor Rau Moreno · 1 shared paper, 2026 · strength 0.21
  10. Mónica Isabel Meneses Medina · 1 shared paper, 2022 · strength 0.17
  11. Taiane Francieli Rebelatto · 1 shared paper, 2019 · strength 0.10
  12. Susan Elaine Bates · 1 shared paper, 2020 · strength 0.08
  13. Andrea J. Bullock · 1 shared paper, 2020 · strength 0.08
  14. Darren S. Sigal · 1 shared paper, 2020 · strength 0.08
  15. Andrew Eugene Hendifar · 1 shared paper, 2020 · strength 0.08
  16. Fabienne Portales · 1 shared paper, 2020 · strength 0.08
  17. Do‐Youn Oh · 1 shared paper, 2020 · strength 0.08
  18. Christelle de la Fouchardière · 1 shared paper, 2020 · strength 0.08
  19. Anthony Maraveyas · 1 shared paper, 2020 · strength 0.08
  20. Volker Heinemann · 1 shared paper, 2020 · strength 0.08
  21. Anup Kasi · 1 shared paper, 2020 · strength 0.08
  22. Chung‐Pin Li · 1 shared paper, 2020 · strength 0.08
  23. Lei Zheng · 1 shared paper, 2020 · strength 0.08
  24. Nathan Bahary · 1 shared paper, 2020 · strength 0.08
  25. Jill Lacy · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.